版本:
中国

BRIEF-Minerva announces amended agreement for MIN-202 in insomnia

May 31 Minerva Neurosciences Inc

* Minerva announces amended agreement for MIN-202 in insomnia

* Janssen cash payments to Minerva of up to $70 million, including $30 million upfront

* Minerva phase 2 development payments totaling $13 million to be waived

* All shares in co held by an affiliate of Janssen to be repurchased at par value

* ‍under amended agreement, Minerva will gain global strategic control of development of MIN-202 to treat insomnia​

* ‍Will retain its current rights to MIN-202 as adjunctive therapy for major depressive disorder​

* Amendment and stock repurchase are conditional upon closing of pending acquisition of Actelion Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐